Acta Vet. Brno 2022, 91: 363-373
https://doi.org/10.2754/avb202291040363
Effectiveness of therapy with low-dosage masitinib on pulmonary hypertension in dogs: a pilot study
References
1. S, Arita N, Hikasa Y 2013: Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs. Can Vet J 54: 255-261
2. KJ, Fine DM, Thombs LA, Gorelick JJ, Durham HE 2009: Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. J Vet Intern Med 23: 1190-1196
<https://doi.org/10.1111/j.1939-1676.2009.0390.x>
3. JF, Rozanski EA, MacGregor J, Betkowski JM, Rush JE 2006: Retrospective evaluation of sildenafil citrate as a therapy for pulmonary hypertension in dogs. J Vet Intern Med 20: 1132-1135
<https://doi.org/10.1111/j.1939-1676.2006.tb00711.x>
4. RJ 2005: PDGF signaling in pulmonary arterial hypertension. J Clin Invest 115: 2691-2694
<https://doi.org/10.1172/JCI26593>
5. M 2015: Dysregulation of tyrosine kinases and use of imatinib in small animal practice. Vet J 205: 180-188
<https://doi.org/10.1016/j.tvjl.2014.12.015>
6. M, Savarino P, Crosara S, Santilli RA, Chiavegato D, Poggi M, Bellino C, La Rosa G, Zanatta R, Haggstrom J, Tarducci A 2008: Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med 22: 120-128
<https://doi.org/10.1111/j.1939-1676.2007.0008.x>
7. AJ, Davison E, Sleeper MM 2010: Clinical efficacy of sildenafil in treatment of pulmonary arterial hypertension in dogs. J Vet Intern Med 24: 850-854
<https://doi.org/10.1111/j.1939-1676.2010.0517.x>
8. P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O 2009: Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 4: e7258
<https://doi.org/10.1371/journal.pone.0007258>
9. AE, Barst RJ, Hoeper MM, Chang HJ, Frantz RP, Fukumoto Y, Galié N, Hassoun PM, Klose H, Matsubara H, Morrell NW, Peacock AJ, Pfeifer M, Simonneau G, Tapson VF, Torres F, Dario Vizza C, Lawrence D, Yang W, Felser JM, Quinn DA, Ghofrani HA 2015: Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant 34: 1366-1375
<https://doi.org/10.1016/j.healun.2015.05.025>
10. HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, Pascoe S 2010: Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 182: 1171-1177
<https://doi.org/10.1164/rccm.201001-0123OC>
11. DS, Biller B, Van Liew CH 2003: Measurement of plasma atrial natriuretic peptide as an indicator of prognosis in dogs with cardiac disease. Can Vet J 44: 293-297
12. M, Yao A, Shiga T, Kinugawa K, Hirata Y, Nagai R 2010: Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J 51: 272-276
<https://doi.org/10.1536/ihj.51.272>
13. M, Sitbon O, Simonneau G 2004: Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425-1436
<https://doi.org/10.1056/NEJMra040291>
14. L, Boon J, Orton EC 1999: Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996. J Vet Intern Med 13: 440-447
15. BW, Atkins CE, Bonagura JD, Fox PR, Häggström J, Fuentes VL, Oyama MA, Rush JE, Stepien R, Uechi M 2019: ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med 33: 1127-1140
<https://doi.org/10.1111/jvim.15488>
16. HB, Stepien RL 2010: Pulmonary hypertension in dogs: diagnosis and therapy. Vet Clin North Am Small Anim Pract 40: 623-641
<https://doi.org/10.1016/j.cvsm.2010.03.011>
17. A, Oláh A, Lux Á, Mátyás C, Németh BT, Kellermayer D, Ruppert M, Török M, Szabó L, Meltzer A, Assabiny A, Birtalan E, Merkely B, Radovits T 2015: Strain and strain rate by speckle-tracking echocardiography correlate with pressure-volume loop-derived contractility indices in a rat model of athlete’s heart. Am J Physiol Heart Circ Physiol 308: H743-H748
<https://doi.org/10.1152/ajpheart.00828.2014>
18. ZP, Hikasa Y 2018: Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats. Vascul Pharmacol 110: 31-41
<https://doi.org/10.1016/j.vph.2018.07.002>
19. ZP, Hikasa Y 2019: Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats. Vascul Pharmacol 122-123: 106599
<https://doi.org/10.1016/j.vph.2019.106599>
20. ZP, Okida A, Higuchi M, Yamano Y, Hikasa Y 2018: Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats. Vascul Pharmacol 100: 41-50
<https://doi.org/10.1016/j.vph.2017.10.006>
21. M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX 2004: Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 68: 75-103
<https://doi.org/10.1016/j.mvr.2004.06.001>
22. NA, Suleiman S, Dreymüller D, Manley PW, Rossaint R, Uhlig S, Martin C, Rieg AD 2017: Imatinib relaxes the pulmonary venous bed of guinea pigs. Respir Res 18: 32
<https://doi.org/10.1186/s12931-017-0514-0>
23. I, Patruno R, Zizzo N, Gadaleta C, Introna M, Zito AF, Gadaleta CD, Ranieri G 2014: Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit Rev Oncol Hematol 91: 98-111
<https://doi.org/10.1016/j.critrevonc.2013.12.011>
24. S, Nagakawa M, Ogi H, Akabane R, Koyama Y, Sakatani A, Ogawa M, Miyakawa H, Shigemoto J, Tokuriki T, Toda N, Miyagawa Y, Takemura N 2020: Use of vertebral left atrial size for staging of dogs with myxomatous valve disease. J Vet Cardiol 30: 92-99
<https://doi.org/10.1016/j.jvc.2020.06.001>
25. D, Perros F, Gambaryan N, Girerd B, Dorfmuller P, Price LC, Huertas A, Hammad H, Lambrecht B, Simonneau G, Launay JM, Cohen-Kaminsky S, Humbert M 2011: C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 184: 116-123
<https://doi.org/10.1164/rccm.201006-0905OC>
26. W, Boswood A, Luis Fuentes V, Brodbelt D, Souttar K, Elliott J 2010: N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract 51: 84-96
<https://doi.org/10.1111/j.1748-5827.2009.00889.x>
27. K, Akagi S, Ogawa A, Kusano KF, Matsubara H, Miura D, Fuke S, Nishii N, Nagase S, Kohno K, Morita H, Oto T, Yamanaka R, Otsuka F, Miura A, Yutani C, Ohe T, Ito H 2012: Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 159: 100-106
<https://doi.org/10.1016/j.ijcard.2011.02.024>
28. R, Saelinger C, Strickland KN, Beaufrčre H, Reynolds CA, Vila J 2012: Tricuspid annular plane systolic excursion (TAPSE) in dogs: reference values and impact of pulmonary hypertension. J Vet Intern Med 26: 1148-1154
<https://doi.org/10.1111/j.1939-1676.2012.00981.x>
29. F, Montani D, Dorfmüller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, Mazmanian M, Fadel E, Mussot S, Mercier O, Hervé P, Emilie D, Eddahibi S, Simonneau G, Souza R, Humbert M 2008: Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 81-88
<https://doi.org/10.1164/rccm.200707-1037OC>
30. M 2008: Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 118: 2372-2379
<https://doi.org/10.1172/JCI33452>
31. C, Visser LC, Kellihan HB, Masseau I, Rozanski E, Clercx C, Williams K, Abbott J, Borgarelli M, Scansen BA 2020: ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs. J Vet Intern Med 34: 549-573
<https://doi.org/10.1111/jvim.15725>
32. RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F 2005: Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821
<https://doi.org/10.1172/JCI24838>
33. F, Pouchelon JL, Poujol L, Lefebvre HP, Trumel C, Daste T, Sampedrano CC, Gouni V, Tissier R, Hawa G, Chetboul V 2009: Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission. J Vet Cardiol 11: 103-121
<https://doi.org/10.1016/j.jvc.2009.07.001>
34. JC, Massard C, Magné N, Bader T, Mansfield CD, Blay JY, Bui BN, Moussy A, Hermine O, Armand JP 2009: Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer 45: 2333-2341
<https://doi.org/10.1016/j.ejca.2009.05.010>
35. RL 2009: Pulmonary arterial hypertension secondary to chronic left-sided cardiac dysfunction in dogs. J Small Anim Pract 50 Suppl 1: 34-43
<https://doi.org/10.1111/j.1748-5827.2009.00802.x>
36. C 1995: New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol 26: 135-136
37. JA, Ruano J, Martin-Duran R, Larman M, Zueco J, Ortiz de Murua JA, Torres A, Figueroa A 1987: Noninvasive determination of pulmonary arterial systolic pressure by continuous wave Doppler. Int J Cardiol 16: 177-184
<https://doi.org/10.1016/0167-5273(87)90249-X>
